title: The Editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk.
authors.affiliation: Department of Gastrointestinal, Medicine and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Bresalier
authors.forename: Vincent E
authors.initials: VE
authors.lastname: Friedewald
authors.forename: Robert E
authors.initials: RE
authors.lastname: Rakel
authors.forename: William C
authors.initials: WC
authors.lastname: Roberts
authors.forename: Gary W
authors.initials: GW
authors.lastname: Williams
mesh_terms: D000544:Alzheimer Disease / Q000517:prevention & control; D001168:Arthritis / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology*; D000075202:Contraindications; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D014943:Global Health; D006801:Humans; D015994:Incidence; D012307:Risk Factors
chemical_list: D052246:Cyclooxygenase 2 Inhibitors